MAPT and Alzheimer disease: We and others have previously reported that the bisecting N-acetylglucosamine (GlcNAc) N-glycan epitope is elevated in CSF in AD,24, 25, 26 and that elevated bisecting GlcNAc levels could predict cognitive decline already at an amyloid/tau negative stage.27